Candel Therapeutics Poised for Breakthrough in Cancer Therapies, Key Trials to Read Out by Year-End | NASDAQ:CADL

Proactive InvestorsOct 17 09:28 ET

This Insider Has Just Sold Shares In Candel Therapeutics

Simply Wall StOct 6 09:05 ET

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

GlobeNewswireOct 4 09:00 ET

Candel Therapeutics, Inc. (NASDAQ:CADL) Most Popular Amongst Individual Investors Who Own 48%, Insiders Hold 30%

Yahoo FinanceSep 13 10:15 ET

Express News | Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to Its Board of Directors

ReutersSep 4 08:00 ET

Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Yahoo FinanceSep 3 08:00 ET